Back to top

FDA approves first at-home starting dose for subcutaneous Leqembi

The U.S. Food and Drug Administration announced it has approved a new starting dosage regimen for the subcutaneous formulation of Leqembi, an amylo...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Biogen Inc. (BIIB)